Accessibility Menu
Genetic Technologies logo

Genetic Technologies(OTC) GNTLF

Market Cap$1.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-100%
1 Year-100%
1 Month-100%
$0.00
+0.00%
+0.00Today
Genetic Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.002025-07-25
Genetic Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-100%USD 1.002025-05-05
1 month-100%USD 1.002025-05-05
3 month-100%USD 1.002024-12-27
Year to date-100%USD 1.002024-12-27
1 year-100%USD 0.072023-11-06
3 year-100%USD 1.302022-07-20
5 year-100%USD 0.092020-07-20
Since inception-100%USD 30.002003-07-10

Genetic Technologies Financials at a Glance

Market Cap

$1.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$13.70M

Net Income (TTM)

-A$22.39M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-25076.29 (Low)

Price

$0.00

Volume

2,000

Open

$0.00

Previous Close

$1.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 27, 2026

GNTLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genetic Technologies

Genetic Technologies Limited is an Australian molecular diagnostics company focused on developing advanced predictive assessment tools for women's health. The company primarily offers BREVAGenplus, a validated risk evaluation test for non-inherited breast cancer, and additional cancer risk assessment tests under the GeneType brand.

Products and Services
  • BREVAGenplus for non-inherited breast cancer risk assessment
  • GeneType tests for colorectal and breast cancer
  • Comprehensive genetic testing services across various applications
Growth Outlook
  • Expansion into new markets, particularly in the United States
  • Ongoing development of diagnostics for cardiovascular disease and diabetes
  • Collaborations with leading research institutions enhance innovation
Financial Highlights
  • Recent quarterly revenue of AUD 413,948, showing potential for growth
  • Trailing twelve months (TTM) revenue of AUD 4,799,772, indicating market interest
  • Current ratio of 0.88 suggests manageable short-term liabilities
Genetic Technologies Limited is positioned in the healthcare sector, specifically within medical diagnostics and research. The company's flagship product, BREVAGenplus, is marketed to healthcare professionals, including breast health specialists and gynecologists. The firm is actively engaged in research collaborations with prestigious institutions, which may drive future innovations and product offerings. The growth outlook appears promising, with plans to expand into new markets and develop additional diagnostic tools. Recent financial data indicates a revenue of AUD 4,799,772 over the trailing twelve months, reflecting a growing interest in the company's offerings. The current ratio of 0.88 suggests that the company is managing its short-term liabilities effectively, which is crucial for sustaining operations and funding future growth initiatives. Overall, Genetic Technologies Limited presents an intriguing opportunity for investors interested in the evolving field of molecular diagnostics, particularly in women's health.
AI Generated • Jul 29, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

58

CEO

Simon Morriss

Website

www.genetype.com

Headquarters

Maroochydore, QL 3065, AU

GNTLF Financials

Key Financial Metrics (TTM)

Gross Margin

50.94%

Operating Margin

-159.30%

Net Income Margin

-156.78%

Return on Equity

-184.98%

Return on Capital

-451.29%

Return on Assets

-194.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.34B

Volume

2.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

A$5.24K

Operating Income

-A$14.02M

EBITDA

-A$14.62M

Operating Cash Flow

-A$13.11M

Capital Expenditure

-A$33.25K

Free Cash Flow

-A$12.14M

Cash & ST Invst.

A$1.01M

Total Debt

A$500.00K

Genetic Technologies Performance Analysis

Genetic Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 4,927,540N/A
20232023-06-30AUD 5,842,69918.6%
20242024-06-30AUD 5,022,640-14.0%
Genetic Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-06-309.1%
Q22023-12-31-12.7%
Q42024-06-3021.2%
Q22024-12-31-91.4%
Genetic Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.06N/A
20232023-06-30AUD -0.0839.8%
20242024-06-30AUD -0.06-23.6%
Genetic Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-06-30-15.2%
Q22023-12-3118.4%
Q42024-06-3029.2%
Q22024-12-3143.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

A$413.95K

-90.0%

Gross Profit

A$413.95K

+126.8%

Gross Margin

100.00%

N/A

Market Cap

$1.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.64

N/A

Employees

55

N/A

Net Income

-A$4.09M

+25.2%

EBITDA

-A$1.33M

+73.7%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

A$1.01M

-79.9%

Total Debt

A$500.00K

-18.4%

Accounts Receivable

A$145.24K

-95.0%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$500.00K

+76.1%

Return on Assets

-1.94%

N/A

Return on Invested Capital

-6.13%

N/A

Free Cash Flow

-A$78.35K

+97.1%

Operating Cash Flow

-A$71.27K

+97.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRCHFH.U. Group Holdings, Inc.
$19.70+0.00%
EVOTFEvotec SE
$6.69+0.00%
RYHTYRyman Healthcare Limited
$6.11+0.00%
CMOPFCosmo Pharmaceuticals N.V.
$74.00-1.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About GNTLF

What is the current price of Genetic Technologies?

Genetic Technologies is trading at $0.00 per share.

What is the 52-week range for Genetic Technologies?

Over the past 52 weeks, Genetic Technologies has traded between $0.00 and $0.00.

How much debt does Genetic Technologies have?

As of the most recent reporting period, Genetic Technologies reported total debt of A$584.49K.

How much cash does Genetic Technologies have on hand?

Genetic Technologies reported A$681.61K in cash and cash equivalents in its most recent financial results.

What is Genetic Technologies’s dividend yield?

Genetic Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services